EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	649	(546/121,514/300).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/05 18:52
L2	2	l1 and imidazopyridin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/05 18:52

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27	AUG 27	USPATOLD now available on STN
NEWS 28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:48:34 ON 05 SEP 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:48:45 ON 05 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2
DICTIONARY FILE UPDATES: 4 SEP 2007 HIGHEST RN 946048-22-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10534741.str





chain nodes :
10 22
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19
chain bonds :
1-10 10-15 12-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-15 11-12 12-13 13-14 13-16
14-15 14-19 16-17 17-18 18-19
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 5-7 6-9 8-9 10-15
exact bonds :
7-8 11-15 11-12 12-13 12-22 14-15
normalized bonds :
13-14 13-16 14-19 16-17 17-18 18-19
isolated ring systems :
containing 1 : 11 :

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 18:49:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 18:49:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 170 TO ITERATE

100.0% PROCESSED 170 ITERATIONS 148 ANSWERS
SEARCH TIME: 00.00.01

L3 148 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 18:49:14 ON 05 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

strictly prohibited.

FILE COVERS 1907 - 5 Sep 2007 VOL 147 ISS 11
FILE LAST UPDATED: 4 Sep 2007 (20070904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1174240 CAPLUS
DOCUMENT NUMBER: 145:489254
TITLE: Preparation of mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
INVENTOR(S): Brehm, Christof; Klein, Thomas; Buhr, Wilm; Chiesa, Maria Vittoria; Palmer, Andreas; Zimmermann, Peter Jan; Simon, Wolfgang-Alexander; Postius, Stefan; Kromer, Wolfgang; Grundler, Gerhard
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 72pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117316	A1	20061109	WO 2006-EP61856	20060426

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-103585 A 20050429
OTHER SOURCE(S): MARPAT 145:489254
GI



I

AB The invention concerns A-Y-X-z-C(O)O-B (A is derived from ACO2H having antipyretic, analgesic, antiphlogistic and/or antiinflammatory properties; B is derived from HOB that are potassium competitive acid blockers; X = bond or linker (e.g. (un)substituted -(CH2)nOm(CH2)pOq(CH2)r (n = 1-7; m = 0, 1; p = 0-7; q = 0, 1; r = 0-7)); Y = -C(O)O- with A attached to the carbonyl carbon; z = bond, -O-, -CHR1- or -NR1- (R1 = H or C1-4 alkyl); or X, Y and z together form a bond; addnl. details including provisos are given in the claims; e.g. [2-[(2,6-dichlorophenyl)amino]phenyl]acetic acid (7S,8R,9R)-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-yl ester (shown as I)) and their salts. The compds. are prodrugs and exhibit in the human and/or animal body antipyretic, analgesic, antiphlogistic and/or antiinflammatory activity as well as gastric acid secretion inhibiting and therefore gastro and intestinal protective activity. Although the methods of preparation are not claimed, prepns. and/or characterization data for 23 examples of I are included. For example, I was prepared from [2-(2,6-dichlorophenylamino)phenyl]acetic acid and (7S,8R,9R)-8-hydroxy-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine using N,N-carbonyldiimidazole in CH2Cl2. Data are provided for the inhibition of gastric acid secretion by 2 examples of I and for inhibition of COX-1/2 by 11 examples of I.

IT 697254-95-8, Methyl 8-[(trans-2,3-dihydro-2-hydroxy-1H-inden-1-yl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate 697254-97-0, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid 697254-99-2, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)amino]-6-[N-(2-methoxyethyl)aminocarbonyl]-2,3-dimethylimidazo[1,2-a]pyridine 697255-01-9, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)amino]-6-(N,N-dimethylaminocarbonyl)-2,3-dimethylimidazo[1,2-a]pyridine 697255-03-1, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)amino]-6-(N-methylaminocarbonyl)-2,3-dimethylimidazo[1,2-a]pyridine 697255-05-3, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide 697255-08-6, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid 697255-10-0, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)oxy]-6-(N,N-dimethylaminocarbonyl)-2,3-dimethylimidazo[1,2-a]pyridine 697255-14-4, 8-[(trans-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)oxy]-6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyridine 697255-16-6, 8-[((1S,2S)-2,3-Dihydro-2-hydroxy-1H-inden-1-yl)oxy]-6-(N,N-dimethylaminocarbonyl)-2,3-dimethylimidazo[1,2-a]pyridine 697255-17-7, 6-(N,N-Dimethylaminocarbonyl)-2,3-dimethyl-8-(trans-1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyloxy)imidazo[1,2-a]pyridine 697255-18-8, 8-[(trans-2,3-Dihydro-2-hydroxy-7-methoxy-1H-inden-1-yl)oxy]-6-(N,N-dimethylaminocarbonyl)-2,3-dimethylimidazo[1,2-a]pyridine 697255-19-9, 8-[(trans-2,3-Dihydro-2-hydroxy-7-methyl-1H-inden-1-

yl)oxy]-6-(N,N-dimethylaminocarbonyl)-2,3-dimethylimidazo[1,2-a]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of mutual prodrug compds. for use as antiinflammatory agents with gastrointestinal protective activity)

RN 697254-95-8 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697254-97-0 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697254-99-2 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N-(2-methoxyethyl)-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-01-9 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-03-1 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N,2,3-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-05-3 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-08-6 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-10-0 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-14-4 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[[6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyridin-8-yl]oxy]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-16-6 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697255-17-7 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, N,N,2,3-tetramethyl-8-[[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-18-8 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-7-methoxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-19-9 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-7-methyl-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1006666 CAPLUS
DOCUMENT NUMBER: 145:377339
TITLE: Preparation of imidazo[1,2-a]pyridine derivatives useful as medicaments for treating gastrointestinal diseases
INVENTOR(S): Bamford, Mark James; Elliott, Richard Leonard; Giblin, Gerard Martin Paul; Naylor, Antoinette; Witherington, Jason; Panchal, Terence Aaron; Demont, Emmanuel Hubert
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 128pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100119	A1	20060928	WO 2006-EP2952	20060322

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

GB 2005-6137	A 20050324
GB 2005-7101	A 20050407
GB 2005-12923	A 20050624
GB 2005-21274	A 20051019

OTHER SOURCE(S): MARPAT 145:377339
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = NH, N-alkyl, O; R1 = H, cyclo/alkyl, alkoxy, NH2 and derivs., etc.; R2 = cyclo/halo/alkyl, NH2, etc.; R3 = H, alkyl; R4, R5 = independently H, alkyl, OH, halo, alkoxy, NH2 and derivs.; or R3CCCR4 = (un)substituted 5- to 6-membered carbocyclyl or heterocyclyl; R6 = H, alkyl, halo, OH, NHCO2-alkyl, NH2 and derivs.; Ar = (un)substituted aryl, 5- to 6-membered monocyclyl or 7- to 12-membered bicyclyl heteroaryl; and their pharmaceutically acceptable salts; with the exception of one specified compound] were prepared for treating diseases or disorders where an acid pump antagonist is required such as gastrointestinal diseases associated with an imbalance in gastric acid (no data). Thus, cyclization of 2-amino-3,5-dibromopyridine with 3-bromo-2-butanone, reaction of the dibromide with (2,6-dimethylphenyl)methanol, and Pd-coupling of the bromide with phenylboronic acid gave imidazopyridine II. Selected I were tested in H+/K+-ATPase activity assays.

IT 910778-94-8P 910778-95-9P 910778-97-1P
910779-08-7P 910779-09-8P, 1-[8-[(2,3-Dihydro-1H-inden-1-yl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]-2(1H)-pyridinone monohydrochloride 910779-10-1P 910779-11-2P
910779-13-4P 910779-14-5P 910779-17-8P
910779-18-9P, 1-[8-[(2,3-Dihydro-1H-inden-1-yl)oxy]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]-2(1H)-pyridinone 910779-19-0P
, 1-[2,3-Dimethyl-8-(1,2,3,4-tetrahydro-1-naphthalenyloxy)imidazo[1,2-a]pyridin-6-yl]-2(1H)-pyridinone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazo[1,2-a]pyridines for treating gastrointestinal diseases)

RN 910778-94-8 CAPLUS
CN Imidazo[1,2-a]pyridin-8-amine, N-[(1R)-2,3-dihydro-1H-inden-1-yl]-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910778-95-9 CAPLUS
CN Imidazo[1,2-a]pyridin-8-amine, N-[(1S)-2,3-dihydro-1H-inden-1-yl]-2,3-dimethyl-6-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910778-97-1 CAPLUS
CN Imidazo[1,2-a]pyridin-8-amine, 2,3-dimethyl-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-6-(1H-1,2,4-triazol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 910779-08-7 CAPLUS
CN 2(1H)-Pyridinone, 1-[8-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-2,3-

dimethylimidazo[1,2-a]pyridin-6-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 910779-09-8 CAPLUS
CN 2(1H)-Pyridinone, 1-[8-[(2,3-dihydro-1H-inden-1-yl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 910779-10-1 CAPLUS
CN 2(1H)-Pyridinone, 1-[8-[[(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910779-11-2 CAPLUS
CN 2(1H)-Pyridinone, 1-[8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910779-13-4 CAPLUS
CN 2(1H)-Pyridinone, 1-[2,3-dimethyl-8-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]imidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910779-14-5 CAPLUS
CN 2(1H)-Pyridinone, 1-[2,3-dimethyl-8-[[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]imidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 910779-17-8 CAPLUS
CN 2(1H)-Pyridinone, 1-[8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 910779-18-9 CAPLUS
CN 2(1H)-Pyridinone, 1-[8-[(2,3-dihydro-1H-inden-1-yl)oxy]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 910779-19-0 CAPLUS
CN 2(1H)-Pyridinone, 1-[2,3-dimethyl-8-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]imidazo[1,2-a]pyridin-6-yl]- (9CI) (CA INDEX NAME)



IT 910779-24-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyridines for treating gastrointestinal diseases)
RN 910779-24-7 CAPLUS
CN 2(1H)-Pyridinone, 1-[8-[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:453215 CAPLUS
DOCUMENT NUMBER: 141:7116
TITLE: Preparation of 8-substituted imidazopyridines as gastric secretion inhibitors
INVENTOR(S): Simon, Wolfgang-Alexander; Postius, Stefan; Kromer, Wolfgang; Buhr, Wilm; Senn-Bilfinger, Joerg; Zimmermann, Peter Jan
PATENT ASSIGNEE(S): Altana Pharma Ag, Germany
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046144	A1	20040603	WO 2003-EP12787	20031115
W: AE, AL, AU, BA, BR, CA, CN, CO, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2506027	A1	20040603	CA 2003-2506027	20031115
AU 2003288071	A1	20040615	AU 2003-288071	20031115
EP 1565465	A1	20050824	EP 2003-779937	20031115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016201	A	20051004	BR 2003-16201	20031115
CN 1708497	A	20051214	CN 2003-80102585	20031115
JP 2006508142	T	20060309	JP 2004-552614	20031115
ZA 2005003224	A	20051122	ZA 2005-3224	20050421
MX 2005PA05117	A	20050701	MX 2005-PA5117	20050512
US 2006100234	A1	20060511	US 2005-534741	20050512
NO 2005002857	A	20050613	NO 2005-2857	20050613
IN 2005MN00608	A	20051007	IN 2005-MN608	20050613
PRIORITY APPLN. INFO.:			EP 2002-25866 A	20021119
			WO 2003-EP12787 W	20031115

OTHER SOURCE(S): MARPAT 141:7116
GI



I



II

AB 8-Substituted imidazopyridines of formula I [R1 = H, alkyl, cycloalkyl, alkoxy, etc.; R2 = H, alkyl, aryl, cycloalkyl, halo, etc.; R3, R4 = H, halo, alkyl, carboxy, alkoxycarbonyl, etc.; R5 = H, alkyl, alkoxy, OH, nitro, (substituted) amino, etc.; R6 = H, alkyl, alkoxy, alkoxycarbonyl, etc.; X = O, NH; Z = (substituted) CH2, (substituted) CH2CH2] are prepared The compds. have gastric secretion inhibiting and excellent gastric and intestinal protective action properties. Thus, II was prepared from Et 2,3-dimethyl-8-(benzyloxy)imidazo[1,2-a]pyridine-6-carboxylate, 1,2-epoxyindane and dimethylamine. II had >30% inhibition of acid secretion in perfused rat stomach at 1 μmol/kg i.d.

IT 697254-99-2P 697255-01-9P 697255-03-1P
697255-05-3P 697255-10-0P 697255-14-4P
697255-16-6P 697255-17-7P 697255-18-8P
697255-19-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridines as gastric secretion inhibitors)

RN 697254-99-2 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N-(2-methoxyethyl)-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-01-9 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-03-1 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-N,2,3-trimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-05-3 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-10-0 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-14-4 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[[6-(methoxymethyl)-2,3-dimethylimidazo[1,2-a]pyridin-8-yl]oxy]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-16-6 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697255-17-7 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, N,N,2,3-tetramethyl-8-[[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl]oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-18-8 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-7-methoxy-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-19-9 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-7-methyl-1H-inden-1-yl]oxy]-N,N,2,3-tetramethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 697254-95-8P 697254-97-0P 697255-08-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridines as gastric secretion inhibitors)
RN 697254-95-8 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697254-97-0 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 697255-08-6 CAPLUS
CN Imidazo[1,2-a]pyridine-6-carboxylic acid, 8-[[(1R,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]oxy]-2,3-dimethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:591349 CAPLUS
DOCUMENT NUMBER: 113:191349
TITLE: Preparation of 8-(indanyloxy)imidazo[1,2-a]pyridines and analogs as gastrointestinal agents
INVENTOR(S): Rainer, Georg; Schaefer, Hartmann; Senn-Bilfinger, Joerg; Grundler, Gerhard; Klemm, Kurt; Simon, Wolfgang Alexander; Riedel, Richard; Postius, Stefan
PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 368158	A1	19900516	EP 1989-120355	19891103
R: ES, GR				
WO 9005136	A1	19900517	WO 1989-EP1316	19891103
W: AU, DK, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				

AU 8946347 A 19900528 AU 1989-46347 19891103
PRIORITY APPLN. INFO.: CH 1988-4120 A 19881107
WO 1989-EP1316 A 19891103

OTHER SOURCE(S): MARPAT 113:191349

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R = benzocycloalkyl group Q1; G = CH(OR5)CH2CH2, CH2CH(OR5)CHMe, CH2CH(OR5)CH2CH, etc.; R1 = H, (hydroxy)alkyl, haloalkyl, cyanoalkyl, alkoxycarbonyl; R2 = H, (hydroxy)alkyl, haloalkyl, cyanoalkyl, CHO, dialkylaminoalkyl; R3, R4 = H, alkoxy, halo; R5 = alkyl, alkanoyl, carbamoyl, etc.] were prepared Thus, I (R = H, R1 = Me, R2 = CHO) was stirred 14 h at 40° with 5-fluoroindene 1,2-oxide in aqueous MeOH containing Et3N to give I (R = trans-indanyl group Q2, R1 = Me, R2 = CHO, R5 = H) which was stirred 3 h with MeOCH2COCl in pyridine containing 4-dimethylamino-pyridine to give I (R = trans-indanyl group Q2, R1 = Me, R2 = CHO, R5 = COCH2OMe). The latter was stirred with NaBH4 in aqueous MeOH to give I (R = trans-indanyl group Q2, R1 = Me, R2 = CH2OH, R5 = COCH2OMe) which had ED50 of 0.8 μ mol/kg i.v. against pentagastrin-stimulated gastric acid secretion in rats.

IT 121081-93-4P 121098-85-9P 130014-58-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of gastrointestinal agents)

RN 121081-93-4 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121098-85-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(5-fluoro-2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 130014-58-3 CAPLUS

CN Carbonochloridic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, monohydrochloride, trans- (9CI)

(CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 129988-57-4P 129988-58-5P 129988-59-6P
129988-60-9P 129988-61-0P 129988-62-1P
129988-63-2P 129988-64-3P 129988-65-4P
129988-66-5P 129988-67-6P 129988-68-7P
129988-69-8P 129988-70-1P 129988-71-2P
129988-72-3P 129988-73-4P 129988-74-5P
129988-75-6P 129988-76-7P 129988-77-8P
129988-78-9P 129988-79-0P 129988-80-3P
129988-81-4P 129988-82-5P 129988-83-6P
129988-84-7P 129988-85-8P 129988-86-9P
129988-87-0P 129988-88-1P 129988-89-2P
129988-90-5P 129988-91-6P 129988-92-7P
129988-93-8P 129988-94-9P 129988-95-0P
129988-96-1P 129988-97-2P 129988-98-3P
129988-99-4P 129989-00-0P 129989-01-1P
129989-02-2P 129989-03-3P 129989-04-4P
129989-05-5P 129989-06-6P 129989-07-7P
129989-08-8P 129989-09-9P 129989-10-2P
129989-11-3P 130014-55-0P 130014-56-1P
130014-57-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as gastrointestinal agent)

RN 129988-57-4 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-58-5 CAPLUS

CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2,3-dihydro-2-[(4-

methoxyphenyl)methoxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-59-6 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2,3-dihydro-2-[(3,4,5-trimethoxyphenyl)methoxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-60-9 CAPLUS
CN Acetic acid, methoxy-, 5-fluoro-2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-61-0 CAPLUS
CN Cyclopropanecarboxylic acid, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-62-1 CAPLUS
CN Benzeneacetic acid, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-63-2 CAPLUS
CN 2-Furancarboxylic acid, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-64-3 CAPLUS
CN Carbamic acid, dimethyl-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI)

(CA INDEX NAME)

Relative stereochemistry.



RN 129988-65-4 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2-[(aminocarbonyl)oxy]-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-66-5 CAPLUS
CN Carbamic acid, (2-hydroxyethyl)-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-67-6 CAPLUS
CN Carbamic acid, (1,1-dimethylethyl)-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-68-7 CAPLUS
CN Carbamic acid, (2-hydroxyethyl)methyl-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-69-8 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-methoxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-70-1 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2-(benzoyloxy)-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-71-2 CAPLUS
CN Benzoic acid, 3-methoxy-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-72-3 CAPLUS
CN Benzoic acid, 2-methoxy-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-73-4 CAPLUS
CN Benzoic acid, 3,4-dimethoxy-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-74-5 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2,3-dihydro-2-[[(phenylamino)carbonyl]oxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-75-6 CAPLUS
CN 4-Morpholinecarboxylic acid, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-76-7 CAPLUS
CN Carbamic acid, (4-methoxyphenyl)-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-77-8 CAPLUS
CN Acetic acid, methoxy-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-78-9 CAPLUS
CN Propanoic acid, 2-methoxy-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-79-0 CAPLUS
CN Propanoic acid, 2-methoxy-, 5-fluoro-2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-80-3 CAPLUS
CN Carbonic acid, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-81-4 CAPLUS
CN Acetic acid, (2-methoxyethoxy)-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-82-5 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-83-6 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2-(benzoyloxy)-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-84-7 CAPLUS
CN Benzoic acid, 4-methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-85-8 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-86-9 CAPLUS
CN Benzeneacetic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-87-0 CAPLUS
CN 2-Furancarboxylic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-88-1 CAPLUS
CN Benzoic acid, 3,4,5-trimethoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-89-2 CAPLUS
CN Benzoic acid, 3-methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-90-5 CAPLUS
CN Benzoic acid, 2-methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-91-6 CAPLUS

CN Benzoic acid, 2,6-dimethoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-92-7 CAPLUS
CN Acetic acid, methoxy-, 5-fluoro-1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-93-8 CAPLUS
CN Acetic acid, methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-94-9 CAPLUS
CN Acetic acid, methoxy-, 1-[(3-cyano-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-95-0 CAPLUS
CN Propanoic acid, 2-methoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-96-1 CAPLUS
CN Propanoic acid, 2-methoxy-, 5-fluoro-1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



RN 129988-97-2 CAPLUS
CN Acetic acid, (2-methoxyethoxy)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-98-3 CAPLUS
CN Carbonic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129988-99-4 CAPLUS
CN Imidazo[1,2-a]pyridine-2-carboxaldehyde, 8-[(2,3-dihydro-2-methoxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-00-0 CAPLUS
CN Carbamic acid, dimethyl-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-01-1 CAPLUS
CN 4-Morpholinecarboxylic acid, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-02-2 CAPLUS
CN Carbamic acid, (2-hydroxyethyl)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-03-3 CAPLUS
CN Carbamic acid, (2-hydroxyethyl)methyl-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-04-4 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2-[(aminocarbonyl)oxy]-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-05-5 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2,3-dihydro-2-[[(phenylamino)carbonyl]oxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-06-6 CAPLUS
CN Carbamic acid, (2,4-dimethoxyphenyl)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-07-7 CAPLUS
CN Carbamic acid, (1,1-dimethylethyl)-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-08-8 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[5-fluoro-2,3-dihydro-2-(phenylmethoxy)-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-09-9 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[5-fluoro-2,3-dihydro-2-(phenylmethoxy)-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-10-2 CAPLUS
CN Benzoic acid, 4-methoxy-, 5-fluoro-1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 129989-11-3 CAPLUS
CN Benzoic acid, 4-methoxy-, 5-fluoro-2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 130014-55-0 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[[2-[(2,6-dimethoxyphenyl)methoxy]-2,3-dihydro-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 130014-56-1 CAPLUS
CN Carbamic acid, (2,4-dimethoxyphenyl)-, 2,3-dihydro-1-[[3-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-8-yl]oxy]-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 130014-57-2 CAPLUS
CN Benzoic acid, 3,4-dimethoxy-, 1-[(3-formyl-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-1H-inden-2-yl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:423515 CAPLUS
DOCUMENT NUMBER: 111:23515

TITLE: Diazoles, their preparation, and their use in treating gastrointestinal disorders

INVENTOR(S): Senn-Bilfinger, Joerg; Grundler, Gerhard; Schaefer, Hartmann; Klemm, Kurt; Rainer, Georg; Schudt, Christian; Simon, Wolfgang Alexander; Riedel, Richard; Postius, Stefan

PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.

SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 299470	A1	19890118	EP 1988-111302	19880714
EP 299470	B1	19961204		
R: ES, GR				
WO 8900570	A1	19890126	WO 1988-EP638	19880714
W: AU, DK, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8821261	A	19890213	AU 1988-21261	19880714
AU 615666	B2	19911010		
EP 370056	A1	19900530	EP 1988-907054	19880714
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
HU 52097	A2	19900628	HU 1988-4838	19880714
HU 204828	B	19920228		
JP 02504271	T	19901206	JP 1988-506300	19880714
CA 1327796	C	19940315	CA 1988-572025	19880714
AT 145907	T	19961215	AT 1988-111302	19880714
ZA 8805129	A	19890222	ZA 1988-5129	19880715
IL 87118	A	19930131	IL 1988-87118	19880715
CN 1031842	A	19890322	CN 1988-106089	19880716
DK 9000121	A	19900115	DK 1990-121	19900115
NO 9000202	A	19900115	NO 1990-202	19900115
US 5112834	A	19920512	US 1990-445611	19900116

PRIORITY APPLN. INFO.: CH 1987-2709 A 19870716
CH 1988-390 A 19880204
WO 1988-EP638 A 19880714

OTHER SOURCE(S): MARPAT 111:23515

GI For diagram(s), see printed CA Issue.

AB Diazoles [I; R1 = H, halo; R2 = H, C1-4 alkyl, hydroxy-, halo-, cyano-C1-4-alkyl, C1-4 alkoxycarbonyl; R3 = H, (un)substituted C1-4 alkyl, NO, NO2, (di)(C1-4 alkyl)amino, C1-4 alkoxycarbonyl; R4, R5 = H, C1-4 alkyl, alkoxy, halo, CF3; R6 = H, C1-4 alkyl; n = 1,2; G1 = CH, N; G2 = O, NH, C1-4 alkylimino, C1-4 alkylene; G3 = hydroxy-C3-5-alkylene; G4 = S, O, CH:CH] and their salts, useful in treating gastrointestinal disorders, were prepared 8-Amino-2-methylimidazo[1,2-a]pyridine in Et2O was treated with Al2O3 and the mixture stirred 30 min at room temperature, treated with indene 1,2-oxide, and stirred 2-48 h at room temperature to give 8-(2-trans-hydroxy-2,3-dihydro-1-indenylamino)-2-methylindiazo[1,2-a]pyridine (II). The 3-Me derivative of II, at 0.3 μmol/kg intradudodenally reduced the lesion index of the stomach of rats 25% after acetylsalicylic acid ulcer provocation and decreased HCl secretion 4.0-27%.

IT 121082-21-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in synthesis of imidazopyridine gastrointestinal tract protective agent)

RN 121082-21-1 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[[2,3-dihydro-2-[(methylsulfonyl)oxy]-1H-inden-1-yl]oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 121081-87-6P 121081-88-7P 121081-89-8P
121081-90-1P 121081-91-2P 121081-92-3P
121081-93-4P 121081-94-5P 121081-95-6P
121081-96-7P 121081-97-8P 121081-98-9P
121081-99-0P 121082-00-6P 121082-03-9P
121082-04-0P 121082-05-1P 121082-06-2P
121082-07-3P 121082-08-4P 121082-09-5P
121082-10-8P 121082-11-9P 121082-12-0P
121082-13-1P 121082-14-2P 121098-83-7P
121098-84-8P 121098-85-9P 121154-38-9P
121154-39-0P 121154-40-3P 121154-41-4P
121154-42-5P 121154-43-6P 121154-44-7P
121154-45-8P 121154-46-9P 121155-44-0P
121209-15-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as gastrointestinal tract protective agent)

RN 121081-87-6 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-88-7 CAPLUS
CN 1H-Inden-2-ol, 1-[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-89-8 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-90-1 CAPLUS
CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-91-2 CAPLUS
CN 2-Naphthalenol, 1-[(2,3-dimethylimidazo[1,2-a]pyridin-8-yl)oxy]-1,2,3,4-tetrahydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-92-3 CAPLUS
CN Imidazo[1,2-a]pyridine-3-acetonitrile, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-93-4 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-94-5 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-95-6 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-96-7 CAPLUS
CN 1H-Inden-2-ol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●x HCl

RN 121081-97-8 CAPLUS
CN 2-Naphthalenol, 1,2,3,4-tetrahydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-98-9 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121081-99-0 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-00-6 CAPLUS
CN 2-Naphthalenol, 1,2,3,4-tetrahydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-03-9 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)amino]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-04-0 CAPLUS
CN 2-Naphthalenol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-1,2,3,4-tetrahydro-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● x HCl

RN 121082-05-1 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 6-chloro-8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-06-2 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 6-chloro-8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-07-3 CAPLUS
CN 1H-Inden-2-ol, 1-[(6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-08-4 CAPLUS
CN 1H-Inden-2-ol, 1-[(3-amino-6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-09-5 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(5-fluoro-2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-10-8 CAPLUS
CN 1H-Inden-2-ol, 5-fluoro-2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-11-9 CAPLUS
CN 1H-Inden-2-ol, 5-fluoro-2,3-dihydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-12-0 CAPLUS
CN 1H-Inden-2-ol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-5-fluoro-2,3-dihydro-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●x HCl

RN 121082-13-1 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-14-2 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121098-83-7 CAPLUS
CN 1H-Inden-2-ol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121098-84-8 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)amino]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121098-85-9 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(5-fluoro-2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121154-38-9 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-39-0 CAPLUS
CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-40-3 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-41-4 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-42-5 CAPLUS
CN 1H-Inden-2-ol, 1-[(3-amino-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, hydrochloride, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 121154-43-6 CAPLUS
CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-44-7 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-45-8 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, (1S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121154-46-9 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 2-methyl-8-[(1,2,3,4-tetrahydro-2-hydroxy-1-naphthalenyl)oxy]-, (1S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121155-44-0 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121209-15-2 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxaldehyde, 8-[(2,3-dihydro-2-hydroxy-1H-inden-1-yl)oxy]-2-methyl-, (1S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 121082-30-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for gastrointestinal tract protective agent)
RN 121082-30-2 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, methanesulfonate (ester), trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 121081-89-8 121082-19-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in synthesis of imidazopyridine gastrointestinal tract protective agent)
RN 121081-89-8 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-1-[(2-methylimidazo[1,2-a]pyridin-8-yl)oxy]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 121082-19-7 CAPLUS
CN 1H-Inden-2-ol, 1-[(6-chloro-2-methyl-3-nitrosoimidazo[1,2-a]pyridin-8-yl)oxy]-2,3-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1989:154298 CAPLUS
DOCUMENT NUMBER: 110:154298
TITLE: Substituted imidazo[1,2-a]pyridines and -pyrazines useful as ulcer inhibitors, drugs containing them, and processes for their preparation
INVENTOR(S): Senn-Bilfinger, Joerg; Grundler, Gerhard; Schaefer,

Hartmann; Klemm, Kurt; Rainer, Georg; Riedel, Richard; Schudt, Christian; Simon, Wolfgang
PATENT ASSIGNEE(S): Byk Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 290003	A2	19881109	EP 1988-107138	19880504
EP 290003	A3	19881228		
R: ES, GR				
WO 8808843	A2	19881117	WO 1988-EP368	19880504
WO 8808843	A3	19881201		
W: AU, DK, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8816860	A	19881206	AU 1988-16860	19880504
ZA 8803169	A	19881228	ZA 1988-3169	19880504

PRIORITY APPLN. INFO.: CH 1987-1771 A 19870508
WO 1988-EP368 A 19880504
OTHER SOURCE(S): MARPAT 110:154298
GI



I

AB The title compds. [I; R1 = H, halo, C1-4 alkyl, alkoxy, alkoxycarbonyl, cyano; R2 = H, C1-4 alkyl, hydroxyalkyl, haloalkyl, cyanoalkyl, alkoxycarbonyl; R3 = R2, CHO, C1-4 aminoalkyl, NO, NO2, amino; R4, R5 = H, C1-4 alkyl, alkoxy, halo, CF3; R6 = H, C1-4 alkyl; X1 = CH, N; X2 = O, imino, S, CH, C1-4 alkylene; X3 = (CH2)n (n = 2-5), CH:CHCH2, CH:CHCH2CH2, CH2CH:CHCH2; X4 = S, O, CH:CH], useful as ulcer inhibitors, were prepared NaH was added to 8-hydroxy-2,3-dimethylimidazo[1,2-a]pyridine in DMF and the mixture was stirred 30 min at room temperature 1-Chloroindane was then added and the mixture was stirred 4 h at 50° to give 8-(2,3-dihydro-1-indenyloxy)-2,3-dimethylimidazo[1,2-a]pyridine. The latter at 3.0 μmol/kg i.v. in rats gave 62% inhibition of stomach acid secretion and 100% inhibition of aspirin-induced ulcers.
IT 119858-29-6P 119858-30-9P 119858-31-0P
119858-32-1P 119858-33-2P 119858-36-5P
119858-38-7P 119858-48-9P 119858-50-3P
119885-10-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as ulcer inhibitor)

RN 119858-29-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 119858-30-9 CAPLUS

CN Imidazo[1,2-a]pyridinium, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-1,2,3-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 119858-31-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 2,3-dimethyl-8-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)



RN 119858-32-1 CAPLUS

CN Imidazo[1,2-a]pyridine-3-acetonitrile, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-

2-methyl- (9CI) (CA INDEX NAME)



RN 119858-33-2 CAPLUS
CN Imidazo[1,2-a]pyridine, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 119858-36-5 CAPLUS
CN Imidazo[1,2-a]pyridin-8-amine, N-(2,3-dihydro-1H-inden-1-yl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 119858-38-7 CAPLUS
CN Imidazo[1,2-a]pyridin-8-amine, N-(2,3-dihydro-1H-inden-1-yl)-2-methyl- (9CI) (CA INDEX NAME)



RN 119858-48-9 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-1H-inden-1-yl)oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 119858-50-3 CAPLUS
CN Imidazo[1,2-a]pyridine-3-methanol, 8-[(2,3-dihydro-1H-inden-1-yl)amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 119885-10-8 CAPLUS
CN Imidazo[1,2-a]pyridin-8-amine, 2-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:138443 CAPLUS
DOCUMENT NUMBER: 106:138443
TITLE: Imidazopyridines and -pyrazines as antiulcer agents
INVENTOR(S): Ueda, Ikuo; Shiokawa, Youichi; Take, Kazuhiko; Itani, Hiromichi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 204285	A1	19861210	EP 1986-107418	19860602
EP 204285	B1	19920115		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8603805	A	19870429	ZA 1986-3805	19860521
US 4725601	A	19880216	US 1986-865331	19860521
FI 8602210	A	19861205	FI 1986-2210	19860526
DK 8602503	A	19861205	DK 1986-2503	19860528
CA 1257264	A1	19890711	CA 1986-510496	19860530
JP 62016483	A	19870124	JP 1986-128941	19860602
AT 71625	T	19920215	AT 1986-107418	19860602
NO 8602208	A	19861205	NO 1986-2208	19860603
HU 40798	A2	19870227	HU 1986-2332	19860603
CN 86104313	A	19870304	CN 1986-104313	19860603
ES 555653	A1	19871201	ES 1986-555653	19860603
AU 8658345	A	19861211	AU 1986-58345	19860604
AU 593802	B2	19900222		
US 4782055	A	19881101	US 1986-942379	19861216

PRIORITY APPLN. INFO.:

GB 1985-14080	A	19850604
GB 1985-30878	A	19851216
US 1986-865331	A2	19860521
EP 1986-107418	A	19860602
GB 1986-27736	A	19861120

OTHER SOURCE(S): CASREACT 106:138443; MARPAT 106:138443
GI



I



II

AB The title compds. [I; R1 = alkenyl, alkynyl, alkadienyl, alkenyloxyalkyl, alkynyloxyalkyl (protected) carboxyalkynyloxyalkyl; R2 = H, alkyl, aryl; R3 = (substituted) aralkyl; X = O, NH; Y = CH, N] were prepared as antiulcer agents. Thus, (benzyloxy)pyridinamine II cyclocondensed with ClCH2COMe to give I (R1 = H, R2 = Me, R3 = 2-ClC6H4CH2, X = O, Y = CH). This was condensed with HCHO and Me2NH, followed by methylation and treatment with HC.tplbond.CCH2OH, to give I (R1 = CH2OCH2C.tplbond.CH, R2 = Me, R3 = 2-ClC6H4CH2, X = O, Y = CH) (III). In rats 32 mg III/kg orally gave 98.2% inhibition of EtOH-induced ulcers and 100% inhibition of stress-induced ulcers.

IT 107230-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiulcer agent)

RN 107230-22-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-methyl-3-(2-propynyl)-8-[(1,2,3,4-tetrahydro-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	37.83	210.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.46	-5.46

STN INTERNATIONAL LOGOFF AT 18:50:08 ON 05 SEP 2007